Resveratrol Modulates Bone Mineral Density and Bone Mineral Content in A Rat Model of Male Hypogonadism

作     者：Hussein F.Sakr Boudaka Ammar Amira AlKharusi I Al-Lawati Mahmoud AlKhateeb Basim H Elesawy Hussein F.Sakr;Boudaka Ammar;Amira AIKharusi;I Al-Lawati;Mahmoud AIKhateeb;Basim H Elesawy

作者机构：Department of PhysiologyCollege of Medicine and Health SciencesSultan Qaboos UniversityMuscat 123Oman Medical Physiology DepartmentFaculty of MedicineMansouraUniversityMansoura 35516Egypt Basic Medical Sciences DepartmentCollege of Medicine at King Saud bin Abdulaziz University for Health Sciences(KSAU-HS)Riyadh 11481Saudi Arabia Department of Clinical Laboratory SciencesCollege of Applied Medical SciencesTaif UniversityTaif 21944Saudi Arabia 

出 版 物：《Chinese Journal of Integrative Medicine》 (中国结合医学杂志（英文版）)

年 卷 期：2023年第29卷第2期

页      面：146-154页

核心收录：

学科分类：1006[医学-中西医结合] 1002[医学-临床医学] 10[医学] 100602[医学-中西医结合临床] 

基　　金：Supported by Sultan Qaboos University Internal Grant/Medicine/Physiology/18/02。 

主　　题：osteoporosis male hypogonadism resveratrol receptor activator of nuclear factor-kappa 

摘      要：Objective: To determine whether resveratrol(Res) can correct osteoporosis induced in a rat model of male hypogonadism. Methods: Thirty-two rats were randomly divided into 4 groups, 8 in each group;1) a control sham group: underwent a similar surgical procedure for induction of orchiectomy(ORCD) without ligation of any arteries or veins or removal of the testis and epididymis;2) a control + Res-treated group(Con+Res):underwent sham surgery similar to the control, but was then treated with Res, as described below;3) an ORCDinduced group: bilateral ORCD surgery as described above, and 4) a ORCD+Res-treated group: bilateral ORCD surgery followed by Res treatment. Res treatment began 4 weeks after ORCD and continued for 12 weeks. After 12 weeks, bone mineral density(BMD) and bone mineral content(BMC) were measured in the tibia and femur of each rat’s right hind leg. Blood levels of bone turnover indicators such as deoxypyridinoline(Dpd), N-telopeptide of type Ⅰ collagen(NTXⅠ), alkaline phosphatase(ALP), and osteocalcin(OC), as well as receptor activator of nuclear factor kappa B(RANK) and osteoprotegerin(OPG) were assessed. Results: ORCD significantly decreased BMD(P0.01) and significantly increased bone resorption, manifested by increased RANK. In addition, it inhibited serum levels of OPG and OC. Res treatment after ORCD effectively increased serum levels of bone formation markers such as OPG and OC, compared with testisectomized rats(P0.05). Conclusion:Res could ameliorate bone loss induced by male hypogonadism, possible via restoration of the normal balance between RANK and OPG.